When was vivoVerse founded?

vivoVerse was founded in 2015 and raised its 1st funding round 4 years after it was founded.

Where is vivoVerse located?

vivoVerse is headquartered in Austin, United States.

How many employees does vivoVerse have?

As of Sep 30, 2026, the latest employee count at vivoVerse is 12.

Is vivoVerse a funded company?

vivoVerse is a funded company, having raised an undisclosed amount across 8 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Apr 01, 2019.

When was the latest funding round of vivoVerse?

vivoVerse's latest funding was a $***** Grant (prize money) round on Dec 17, 2025, with participation from 1 investor.

Where does vivoVerse rank among its competitors?

vivoVerse ranks 7th amongst 17 active competitors, of which 2 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was vivoVerse, which secured $1.16M in Dec, 2025.

Who are the top competitors of vivoVerse?

vivoVerse's top competitors include Pocket Naloxone, ACS and Celero Systems. Among them, vivoVerse secured the most recent funding round in December, 2025.

vivoVerse - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of a drug screening platform using in vivo small animal models. It offers C. elegans-based drug discovery and toxicity studiy platform that uses microfluidics, automation, and AI/ML technologies. It It serves the agrichemical, petrochemical, biopharmaceutical, and nutraceutical industries.

Website: vivoverse.com
Social
Email ID: *****@vivoverse.com

Key Metrics

Founded Year

2015

Location

Austin, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Dec 17, 2025, $*****

Investors

HHS

Ranked

7^th among 17 active competitors

Employee Count

12 as on Sep 30, 2026

Similar Companies

Pocket Naloxone & 16 more

View vivoVerse's full profile

vivoVerse has raised funding over 8 rounds. Its first funding round was on Apr 01, 2019. Its latest funding round was a Grant (prize money) round on Dec 17, 2025 for $*****. 1 investor participated in its latest round. vivoVerse has 1 institutional investor.

Here is the list of recent funding rounds of vivoVerse:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 17, 2025	3923512	Grant (prize money)	2809554	6627527	8098527	7050578
Sep 02, 2025	1223403	Grant (prize money)	9842654	8569692	3609315	HHS
Dec 17, 2024	3640969	Grant (prize money)	2354585	6260619	5949481	HHS

Access funding benchmarks and valuations. Sign up today!

View details of vivoVerse's funding rounds and investors

The founders of vivoVerse are Evan Hegarty and Adela Ben Yakar.

Here are the details of vivoVerse's key team members:

Evan Hegarty: Co-Founder of vivoVerse.
Contact Info: 1 email address
Adela Ben Yakar: Co-Founder & CSO of vivoVerse and founder of 1 other company.

View details of vivoVerse's Founder profiles and Board Members

vivoVerse's employee count trend

vivoVerse has 12 employees as of Sep 26. Here is vivoVerse's employee count trend over the years:

Uncover vivoVerse's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of vivoVerse include Pocket Naloxone, ACS and Celero Systems. Here is the list of Top 10 competitors of vivoVerse, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Pocket Naloxone 2019, Bethesda (United States), Series A	Developer of FDA approved devices for opioid overdoses management	$6.16M	Advisors.Fund, Warren Point Capital & 6 others	45/100
2nd	ACS 1976, Toronto (Canada), Unfunded	Manufacturer of sensors for monitoring alcohol content in the body	-	-	41/100
3rd	Celero Systems 2017, Lincoln (United States), Funding Raised	Developer of a device for the detection of opioid overdose	-	Kyto Technology & Life Science, Foothill Ventures	33/100
4th	PinPoint Testing Little Rock (United States), Series A	Provider of tool for drug testing services in laboratories	$1.18M	-	31/100
5th	Pharmchek 1971, Fort Worth (United States), Acquired	Manufacturer of sweat patch for long-term and continuous drug testing	-	-	30/100
6th	NIRLAB 2018, Orsieres (Switzerland), Acquired	AI and cloud based health assessment tool for providers	-	Venturelab, Venture Kick	29/100
7th	vivoVerse 2015, Austin (United States), Funding Raised	Provider of a drug screening platform using in vivo small animal models	-	HHS	28/100
8th	Labb 2017, Portsmouth (United States), Unfunded	App based platform offering drug testing system	-	-	24/100
9th	Oral Cube 2014, Salt Lake City (United States), Unfunded	Provider of drug and alcohol testing devices for healthcare providers and clinics	-	-	24/100
10th	ION-GAS 2014, Dortmund (Germany), Unfunded	Developer of instrument to detect drugs	-	-	23/100